PeptideApprove vs AllayPay

AllayPay is a generalist high-risk processor that onboards peptide merchants among many other categories. PeptideApprove is built only for peptide brands. Here is what that difference means in practice.

§ Verdict

Pick PeptideApprove if you want fixed 5% all-in pricing, faster sponsor-bank review, and payout flexibility. Pick AllayPay if you want cross-category coverage and don't mind quote-only pricing.

Feature-by-feature

Side-by-side comparison.

Feature	PeptideApprove	AllayPay
Industry rate range	5–15% typical for peptide MIDs	5–15%
Serves RUO + Healthcare	✓ Both tracks — RUO label-compliance path or LegitScript-certified pharmacy path	Unclear / case-by-case
Pricing model	Statement-audited. Published savings vs. your current rate.	Quote-only, case-by-case
Reserve schedule	Statement-audited. Released on a published schedule.	Quote-only, typically 180 days
LegitScript bundled at cost	✓ Yes	— Pass-through
Two pre-underwritten backends	✓ Yes	— No
Peptide-specific underwriting	✓ Peptide-only by design	— Generalist high-risk
Onboards MATCH-listed merchants	Yes, with documented cause + LegitScript	Yes (broad)
Onboarding (compliant merchant)	10 days	"Quick" (claimed)
Application fee	$0	Varies
Won't onboard guarantee	If we can't lower your TCO, we won't onboard you	—

The honest assessment

Where each one actually wins.

PeptideApprove wins on:

Pricing transparency. Statement-audited model means you see exact line-item deltas before signing.
Pre-underwritten backup acquirer. Every PeptideApprove merchant has a warm secondary MID at a different bank. AllayPay uses a single acquirer per merchant.
Peptide-specific underwriting. We onboard only peptide brands and configure every account around BRAM. AllayPay is a generalist high-risk processor — their underwriting screen has to accommodate dozens of categories.
LegitScript at-cost. $1,075/year passed through with no markup, plus pre-screening to halve the certification cycle.
Onboarding speed. 10 days vs. industry-standard 4–6 weeks.

AllayPay wins on:

Cross-category coverage. AllayPay onboards CBD, nutraceuticals, supplements, and several other high-risk categories. If your portfolio spans categories beyond peptides, AllayPay's breadth is useful.
Established brand. AllayPay has been in the high-risk space for years. If brand age is your decision criterion, that history matters.
Phone-first sales. AllayPay takes inbound sales calls before quoting. PeptideApprove is web + email until you've seen your number.

Decision guide

Which one should you actually pick?

If you sell only peptides

PeptideApprove. Peptide-specific underwriting and pricing transparency outweigh AllayPay's breadth.

If you sell peptides plus CBD or supplements

AllayPay. We don't onboard CBD. AllayPay's cross-category model is the better fit.

If you're on the MATCH list

Either will onboard you. PeptideApprove requires documented cause + a LegitScript path. AllayPay is broader.

If working capital efficiency matters

PeptideApprove. Our 90-day published reserve releases capital roughly 2× faster than the 180-day industry default.

Send us your current statement. We'll show you what you'd save.

Side-by-side analysis in your inbox within 24 hours. No phone calls. No application fee. If we can't lower your total cost of ownership in year one, we won't onboard you.

Apply now → Apply now